Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13351518 | 0.86 | ALDH1A1 (0.41) | PIK3CDL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6607603 | 0.81 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1KDM4EHSD17B10ALOX15 | |
| SCHEMBL22447842 | 0.79 | PIK3CD (0.42) | PIK3CDL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6392802 | 0.79 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1KDM4EHSD17B10ALOX15 | |
| SCHEMBL15492969 | 0.79 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL8300064 | 0.78 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL22447863 | 0.78 | PIK3CD (0.41) | PIK3CDL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13612711 | 0.76 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1KDM4EHSD17B10ALOX15 | |
| SCHEMBL27815168 | 0.76 | ADH1A (0.44) | L3MBTL1ALDH1A1KDM4EHSD17B10ALOX15 | |
| SCHEMBL22448021 | 0.76 | L3MBTL1 (0.56) | PIK3CDL3MBTL1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | PIK3CD 3435/4885L3MBTL1 3411/4885ALDH1A1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.